XLO

Xilio Therapeutics, Inc.

8.90 USD

Last updated Sep 5, 12:15 UTC

Yesterday HIGH

$9.23

Yesterday LOW

$8.81

52w HIGH

$12.74

52w LOW

$6.47

EPS

-0.33

PE

-26.97

Next Earnings

Nov 12, 2026

Overview News Government Trades Fundamentals

Xilio Therapeutics, Inc. stock is down -3.99% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 September’s closed higher than August.

Benzinga Newsdesk

Wed Aug 12, 2026

Xilio Therapeutics Q2 EPS $(0.33) Beats $(0.59) Estimate, Sales $18.692M Beat $12.720M Estimate

Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.59) by 44.07 percent. This is a 85.27 percent increase over losses of $(2.24) per share
Benzinga Newsdesk

Tue May 12, 2026

Xilio Therapeutics Q1 EPS $(0.58) Beats $(0.66) Estimate, Sales $12.648M Beat $8.520M Estimate

Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.66) by 12.12 percent. This is a 76.71 percent increase over losses of $(2.49) per share from
Benzinga Newsdesk

Fri Apr 17, 2026

Xilio's XTX601 Shows Tumor-Selective Activation And Strong Preclinical Anti-Tumor Activity With Favorable Safety Profile At AACR 2026

XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models Consistent with Xilio's clinically-validated masking technology, XTX601 was well